Pharmacotherapy of the overactive bladder and advances in drug delivery

Clinical Obstetrics and Gynecology

Volumn 45, Issue 1, 2002, Pages 205-217

  Cannon, Tracy Washington ^a   Chancellor, Michael B ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Kaufmann Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BROMOCRIPTINE; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMAKALIM; DESMOPRESSIN; DICYCLOVERINE; DULOXETINE; EMEPRONIUM BROMIDE; FLAVOXATE; HYOSCYAMINE; IMIPRAMINE; LEMAKALIM; LEVODOPA; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; N CYANO N' (2 NITROXYETHYL) 3 PYRIDINECARBOXIMIDAMIDE; NEUROKININ A; NEUROKININ B; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; PROSTAGLANDIN INHIBITOR; RESINIFERATOXIN; SCOPOLAMINE; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; BLADDER DYSFUNCTION; CONFERENCE PAPER; CONSTIPATION; CYSTOSCOPY; DROWSINESS; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; ELDERLY CARE; GENE THERAPY; HEALTH CARE POLICY; HUMAN; NEUROTOXICITY; OVERACTIVE BLADDER; TACHYCARDIA; TREATMENT CONTRAINDICATION; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZHYDRYL COMPOUNDS; BOTULINUM TOXINS; CAPSAICIN; CHOLINERGIC ANTAGONISTS; CRESOLS; CYSTITIS, INTERSTITIAL; DITERPENES; HUMANS; MANDELIC ACIDS; NEUROTOXINS; PHENYLPROPANOLAMINE; URINARY BLADDER; URINARY BLADDER DISEASES; URINATION DISORDERS;

EID: 0036196624     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200203000-00022     Document Type: Conference Paper

References (37)

1. Genitourinary tract patent update
2. Once-a-day controlled- versus immediate-release oxybutynin chloride for urge incontinence
3. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate release oxybutynin
4. Metabolism of drugs by the gastrointestinal tract
5. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of overactive bladder
6. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartate in the treatment of overactive bladder: Results of the OBJECT study
7. Pharmacologic options for the overactive bladder
8. An objective comparison of the effects of parenterally administered drugs in patients suffering from detrusor instability
9. Prospective study utilizing transdermal scopolamine in detrusor instability
10. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat
11. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury
12. The overactive bladder: Pharmacologic basis of drug treatment
13. Effects of ZD6169, a K+(ATP) channel opener, on the micturition reflex in the rat
14. Effect of K+ channel openers, KRN2391 and Ki1769, and Nitroglycerin on the urinary tract of rats in vivo
15. The mammalian tachykinin receptors
16. Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anesthetized rats
17. Mechanisms underlying the recovery of urinary bladder function after spinal cord injury
18. Neurophysiology of micturition and its modification in animal models of human disease
19. Activation of unmyelinated afferent fibers by mechanical stimulation and inflammation of the urinary bladder in the cat
20. Intravesical capsaicin and resiniferatoxin therapy; spicing up the ways that we treat the overactive bladder
21. The capsaicin receptor: A heat-activated ion channel in the pain pathway
22. 2+ dependence in rat trigeminal ganglion cells
23. Long-lasting desensitization of bladder afferents after intravesical resiniferatoxin and capsaicin in the rat
24. Regional differences in the motor response to capsaicin in the guinea pig urinary bladder: Relative role of pre- and postjunctional factors related to neuropeptide-containing sensory nerves
25. Vanilloid receptors: New insights enhance potential as therapeutic target
26. Intravesical capsaicin as a treatment of refractory detrusor hyperreflexia: A dual center study with long-term follow-up
27. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double-blind placebo-controlled study in patients with spinal cord disease. Preliminary results
28. Why red-hot peppers are red-hot
29. Desensitization of bladder sensory fibers by intravesical capsaicin has long-lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction
30. Urodynamic effects of intravesical resiniferatoxin in humans: Preliminary results in stable and unstable detrusor
31. Intravesical resiniferatoxin for the treatment of detrusor hypereflexia refractory to capsaicin
32. Intravesical resiniferatoxin (RTX) improves bladder capacity and decreases incontinence for refractory detrusor hyperreflexia: A multicenter, blinded, randomized, placebo-controlled trial
33. Single dose of intravesical resiniferatoxin for the treatment of interstitial cystitis - Preliminary results of randomised controlled study
34. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction
35. Botulinum A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results
36. Gene therapy using herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: Potential treatment of diabetic bladder dysfunction
37. Gene therapy for urogenital pain; proof of concept with herpes simplex virus expressing preprokephalin (HSV-PPE)